Clinical Trial

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the safety and efficacy of CAR1922T2 T-cell therapy in participants with relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Participants will receive a single infusion of CAR1922T2 T-cells and complete follow-ups over the next three years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Trial Details
NCT Number NCT06879262
Lead Sponsor Tongji Hospital
Conditions R/R NHL
Enrollment 60 participants
Start Date 2026-02-15
Primary Completion 2028-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-06